Remove 2007 Remove Competition Remove Marketing
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

For years, Jazz Pharmaceuticals has dominated the market in treating narcolepsy with cataplexy. But increased competition is on the horizon. Jazz Pharmaceuticals has numerous patents on sodium oxybate and, through litigation, has maintained market exclusivity for many years. Competition starts to heat up.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. Not only that, One Medical accepts insurance and partners with local health systems in most markets where it operates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

Globally, the first rituximab biosimilar, Dr Reddy’s Laboratories’ Reditux, was approved in India in 2007. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.

Sales 59
article thumbnail

Enterprising Yourself At The Top Of The Spine Distributorship Game With Daniel Tighe

Evolve Your Success

He tells his entrepreneurial origin, shedding light on how he tackled the opportunities that came his way and approached marketing. This is 2007. You are so spoiled if you are trying to get into this now because there’s competition in this space for you to reach that next level. To do referral marketing? Not really.

Doctors 246
article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

Lucentis was first approved in the US in 2007 for wet AMD and grew quickly thereafter as additional indications were approved. Roche has US marketing rights to the drug, and booked $1.3 billion in sales from it in 2021, while Novartis made $2.2

FDA 59